Orally inhaled drug performance testing for product development, registration, and quality control
Related Experiment Video
Updated: Apr 23, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Orest Lastow1, Mårten Svensson
11 Medicon Valley Inhalation Consortium, MVIC AB , Medicon Village, Lund, Sweden .
Abstract:
A DPI can be split into three different modules; device, formulation, process. These are developed in parallel, and together with the user they provide the performance of an inhalation product. During product development, these modules are evolving and changing, whereas the requirements on an inhalation product are always expressed in terms of the performance of the final commercial product. To do performance testing during development when the product is not finished presents many challenges and can be confusing and misleading. During development, the performance of the final product is typically being predicted by testing ever changing prototypes. This article describes methods and approaches to manage such development and to, during development, provide relevant predictions of the in vitro and in vivo performances of the final product.
Related Concept Videos
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Release Testing: Overview, Development and Validation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Oral Drug Delivery Systems: Introduction
Inhaled Medications
Preclinical Development: Overview

